INPRISM · PRISM · PHASE 2

One question. Every paper and regulation.

Ask in natural language. Get answers traced to specific paragraphs in specific papers. Compare FDA · NMPA · EMA · ICH side-by-side.

Try with a PDFSample a regulation comparison
14-day Pro trial · Upload any PDF · 50 questions / month free tier
Ask InPrismcite-grounded
▷ What is the FDA-acceptable HCP limit for mAb biosimilars in 2026?
100 ppm is the de facto industry consensus,¹ with FDA accepting 100–500 ppm for case-by-case justification on high-dose mAbs. Recent guidance² further specifies risk-based limits for biosimilars.
¹ FDA Guidance on Q6B · 2024-12 · ¶ 4.3.2
² FDA biosimilar manual · 2025-08 · § 6
01 — THE PROBLEM

You can't keep up.

44,000 PubMed papers were indexed last week. Six major regulators updated their guidance. ICH harmonizes at its own pace.

A keyword search returns 100+ results. You read 5. You missed the answer.

44,000
papers / week (PubMed)
6
regulators updating guidance
100+
avg results per keyword search
5
avg results actually read
02 — THE SOLUTION

Search that understands what you mean.

InPrism combines BM25 keyword retrieval, semantic embedding recall, and reranking. Answers are synthesized with paragraph-level citations — you can verify everything in 30 seconds.

03 — CAPABILITIES

Six capabilities for evidence-grade search.

01

Unified search

PubMed · Embase · Scholar · bioRxiv · CNKI in one box. BM25 + embeddings + reranker.

02

PDF deep Q&A

Upload one or many PDFs. Targeted Q&A with paragraph-level citation, built on PaperQA2.

03

Multi-paper comparison

Pick 3–10 papers, get a comparison table (method · sample · result · conclusion).

04

Regulatory cross-reference

FDA · NMPA · EMA · ICH side-by-side tables with diff highlighting.

05

Citation graph

Pick a paper, trace its citations up and down the network.

06

Regulatory updates

ICH guideline version diffs notified automatically; key changes highlighted.

04 — HOW IT WORKS

A six-step evidence pipeline.

01
Sources
Open (PubMed / bioRxiv) + customer PDFs + commercial DBs (M2+)
02
Parse
MinerU (CN) · Docling (EN) · GROBID (academic metadata)
03
Index
Multi-embedding → Milvus · BM25 + Elasticsearch full-text
04
Retrieve
Dual-route recall → reranker second stage
05
Generate
Multi-vendor LLM gateway · citation grounding · region- and task-aware routing
06
UI
Answer → highlighted source paragraph → one-click jump to PDF
05 — SHOWCASE · REGULATORY CROSS-REFERENCE

FDA vs NMPA vs EMA vs ICH. Side by side.

Pick a topic. Get the four agencies' positions in one table — with diff highlighting.

Stability testing for cell therapy
FDA
NMPA
EMA
ICH
Storage condition
-150°C vapor LN
-150°C vapor LN
≤ -135°C
≤ -130°C★
Stability protocol
Real-time + accelerated
Real-time + stress
Real-time only★
Real-time + accelerated
Validation lots
3 commercial
3 lots (PIC/S aligned)
3 lots
3 lots
Stability indicators
Identity + viability + potency
Identity + viability + potency + impurity★
Identity + viability + potency
Risk-based selection
★ diff-highlighted — values that differ from the majority position. Click any cell in-app for the citing paragraph.
06 — USE CASES

Three questions that took a morning. Now they take seconds.

CM
CMC scientist

“What's the FDA-acceptable HCP limit for mAb biosimilars? — 3 FDA guidance + 5 papers cited.”

Anonymous · v0 placeholder
RA
Regulatory affairs

“Compare FDA · NMPA · EMA on stability testing for cell therapy. — three-column diff table in 8 seconds.”

Anonymous · v0 placeholder
PS
Process scientist

“Recent advances in single-pass TFF for >150 g/L mAb formulations. — 12 papers + citation graph.”

Anonymous · v0 placeholder
07 — PRICING

InPrism at every tier.

Free
50 search queries / month · public sources
Pro
Unlimited search · PDF Q&A · multi-paper compare
Team
+ regulatory cross-reference · citation graph
Enterprise
+ private corpus · custom integrations
See full pricing
08 — COMPLIANCE & DEPLOY

Your corpus stays yours.

✓Uploaded PDFs are stored in your tenant namespace only
✓No customer corpus is used to train shared models
✓CN data residency available on inscinstech.cn
✓Private deployment available for sensitive corpora
✓Audit log of every Q&A request and source retrieved
09 — SAMPLE OUTPUT

An InPrism PDF Q&A session.

app.inscinstech.ai
Ask InPrismcite-grounded
▷ What is the FDA-acceptable HCP limit for mAb biosimilars in 2026?
100 ppm is the de facto industry consensus,¹ with FDA accepting 100–500 ppm for case-by-case justification on high-dose mAbs. Recent guidance² further specifies risk-based limits for biosimilars.
¹ FDA Guidance on Q6B · 2024-12 · ¶ 4.3.2
² FDA biosimilar manual · 2025-08 · § 6
SOURCE PARAGRAPH · ¶ 4.3.2
FDA Guidance on Q6B (2024-12)
“Acceptance criteria for host cell protein content should be established based on risk, with a default position of 100 ppm for typical mAb products; case-by-case justification may extend this to 100–500 ppm where dosing and clinical exposure are characterized...”
11 — FAQ

Common questions

Every claim links to a paragraph in a specific source. If we cannot find evidence, we say so instead of hallucinating.
Public sources are indexed natively; for paywalled databases we honour your institutional access — we never republish.
Team+ tier lets you upload local SOPs or guidance and cross-reference them against FDA / NMPA / EMA / ICH.
Multiple embedding models with a reranker pass. The model mix is region- and task-aware and abstracted from end users.
Want to see all 4 modules in one place?Explore the full inscinstech.ai platform

Find the answer. Cite the source. Move on.

Free tier includes 50 queries / month and PDF Q&A.

Upload a PDFTry a regulation comparison
InPrism · Literature + regulation deep-search agent | inscinstech.ai